• GSK343: Reframing EZH2 Inhibition for Translation

  2026-09-21

  GSK343 offers a precise way to interrogate EZH2-dependent chromatin repression while keeping translational conclusions appropriately bounded. By connecting PRC2 biology with emerging evidence that APEX2 supports TERT expression through DNA repair at repetitive regions, this article outlines a practical strategy for moving from target engagement to mechanistic insight in epigenetic cancer research.

• Valemetostat (DS-3201) Research Workflow

  2026-09-20

  Build a translational Valemetostat workflow that connects EZH2 genotype, PRC2 target engagement, and lymphoma-cell response. The guide separates evidence from optimization advice, helping researchers use this selective epigenetic probe in EZH2 mutant inhibition, follicular lymphoma, and broader lymphoma studies.

• Primidone: From Target Assays to Translational Design

  2026-09-19

  Primidone and Mysoline are more than established neurological medicines: they are useful probes for TRPM3, RIPK1, and selected enzyme assays. This evidence-led guide shows how to connect biochemical potency, assay architecture, model dosing, and translational interpretation without confusing mechanistic plausibility with therapeutic proof.

• Toremifene in Breast Cancer: 20-Year Evidence Review

  2026-09-18

  This review examines how two decades of clinical and translational evidence position toremifene as an oral selective estrogen receptor modulator for hormone receptor–positive breast cancer. Its main contribution is a clinically focused synthesis showing broadly comparable efficacy with tamoxifen, no confirmed overall safety advantage, and a distinct pharmacokinetic profile that may inform treatment selection in selected postmenopausal patients.

• From Reporter Signal to Translational mRNA Insight

  2026-09-18

  A mechanistic and strategic guide to using EZ Cap™ Firefly Luciferase mRNA as a calibrated reporter for mRNA delivery, translation, gene regulation, and in vivo imaging—while accounting for formulation, route, inflammation, and biological context.

• Mouse Toxicology of Decitabine: Methods and Findings

  2026-09-17

  Momparler and Frith established a route-relevant mouse toxicology framework for 5-Aza-2'-deoxycytidine, combining continuous intravenous infusion, sex-specific lethality estimates, and histopathology during acute injury and recovery. The study showed dose-limiting hematopoietic and gastrointestinal toxicity that was largely reversible, while persistent leukopenia highlighted the need for exposure-aware experimental design.

• Rocilinostat (ACY-1215) Workflow Guide

  2026-09-17

  Build selective HDAC6 experiments around α-tubulin acetylation, multiple myeloma viability, and proteasome-inhibitor combinations. This guide also shows how to extend Rocilinostat research into primary-cilia questions without confusing exploratory assays with findings established in SMPD4 developmental models.

• PARP1–FAK–COL5A1 Signaling in Ovarian Cancer

  2026-09-16

  A 2024 Cellular Signalling study established a cholesterol-resistant ovarian cancer model and identified a PARP1–FAK/Src–COL5A1 axis that promotes epithelial–mesenchymal transition. Its combined adaptation, pathway perturbation, tissue analysis, and in vivo design provides a useful framework for cancer biology research focused on cholesterol-linked invasion and tumor progression.

• How EZH2 Shapes eIF4F Inhibitor Resistance in Melanoma

  2026-09-16

  The reference study identifies EZH2 and AKT1 signaling as coordinated resistance nodes that emerge after eIF4F-complex inhibition in BRAFV600E melanoma models. Its time-resolved experiments show why combining eIF4F, EZH2, and AKT1 inhibition can improve activity against both eIF4F inhibitor resistance and vemurafenib resistance.

• Pazopanib in ATRX-Defined Glioma Research

  2026-09-15

  Pazopanib (GW-786034) offers a genotype-aware tool for studying RTK dependence, angiogenesis inhibition, and tumor growth suppression in glioma models. This article translates ATRX-sensitive inhibitor findings into practical assay-design and interpretation strategies.

• Quercetin Suppresses Ferroptosis in Wilson’s Disease

  2026-09-15

  A 2026 Phytomedicine study identifies ferroptosis and phospholipid remodeling as important components of Wilson’s disease-associated liver injury. Using animal and cellular models, lipidomics, target perturbation, and biophysical assays, the authors link Quercetin protection to direct inhibition of the ACSL4/LPCAT3/ALOX15 axis.

• PLGA Nano-Adjuvant Targets Intestinal Immunity in Chicks

  2026-09-14

  A 2026 Poultry Science study developed PEI-LSP-RA-PLGA, a layered PLGA nanoparticle adjuvant designed to combine sustained delivery with intestinal immune targeting in chicks receiving an inactivated H9N2 vaccine. The formulation enhanced systemic IgG and intestinal IgA responses and was associated with CCR9/CCR6, Toll-like receptor, NOD-like receptor, and IgA-production pathways.

• GMA, Neuroinflammation, and Rapid Antidepressant Effects

  2026-09-14

  A Journal of Ethnopharmacology study identifies GMA, a refined combination of Gardeniae Fructus, Moutan Cortex, and Angelica Sinensis Radix, as a rapidly acting antidepressant-like formula in LPS-treated mice. The findings connect behavioral improvement with reduced hippocampal neuroinflammation and restoration of CaMKII–mTOR–BDNF neuroplasticity signaling, while also defining important limits for translation beyond the animal model.

• IWP-2 Wnt Production Inhibitor Workflow

  2026-09-13

  IWP-2 enables upstream control of Porcupine-dependent Wnt secretion for cancer research, pathway validation, and mechanism-focused phenotyping. This practical guide connects concentration selection, apoptosis assay design, and single-nucleus profiling concepts to improve reproducibility without overstating translational evidence.

• TSA and Tumor Immunogenicity: A Translational Lens

  2026-09-12

  Trichostatin A offers a reversible way to interrogate how HDAC-dependent chromatin repression shapes cancer-cell behavior and tumor immunogenicity. This thought-leadership guide connects TSA pharmacology with the CBX2–RACK1–HDAC1 axis, outlining validation strategies, experimental safeguards, and translational boundaries for cancer research.

8656 records 1/578 page Next 12345 下5页 Last page